Replies to post #15981 on Momenta Pharmaceuticals, Inc. (MNTA)

[DewDiligence]

To re-iterate, the main issue in the 40mg-Copaxone patent case is obviousness. MNTA and its co-defendants will argue that giving twice as much Copaxone (approximately) half as often is not a bona fide innovation worthy of patent protection.

[Double_Bagel]

The strange thing is that TEVA is getting clobbered today and there have been lots of PUTS being bought. Here is what TheFlyOnTheWall had to say:

Teva put volume heavy and directionally bearish
Bearish flow noted in Teva with 8,348 puts trading, or 3x expected. Most active are Jan-17 45 puts and Dec-16 47.5 puts, with total volume in those strikes near 2,300 contracts. The Put/Call Ratio is 2.01, while ATM IV is up nearly 2 points on the day. Earnings are expected on November 15th

Yet, there has been absolutely no interest in MNTA. No call buying at all.